2019
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology 2019, 29: 711-719. PMID: 31076187, DOI: 10.1016/j.euroneuro.2019.04.001.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsPharmacological responsePharmacological imagingFunctional MRIRandomized double-blind designResting-state functional MRIAcute pharmacological responsesCitalopram plasma concentrationsPrevalent neuropsychiatric conditionsDouble-blind designMechanism of actionPlacebo scansInfusion paradigmPlasma levelsSSRI effectsDrug challengePatient outcomesPlasma concentrationsDrug infusionInfluence treatmentConstant infusionLarger sample sizePET/MR scansThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2014
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry 2014, 78: 525-533. PMID: 25497691, PMCID: PMC4585531, DOI: 10.1016/j.biopsych.2014.09.010.Peer-Reviewed Original ResearchConceptsSerotonin reuptake transporterSERT bindingFemale transsexualsStart of treatmentSteroid hormone treatmentNew treatment modalitiesTreatment of depressionMedian raphe nucleusHormone plasma levelsTreatment-induced increaseMid-cingulate cortexPositron emission tomographyMechanism of actionTreatment startSerotonergic transmissionEstradiol levelsRaphe nucleusEstrogen treatmentReuptake transporterTreatment modalitiesAndrogen treatmentEpidemiologic findingsPlasma levelsSex hormonesSERT expression